OptimizeRx Corp (Nasdaq: OPRX) reported results for the third quarter ended September 30, 2026, beating analyst expectations for both revenue and earnings per share. The company also updated its financial guidance for fiscal 2026, lowering its full-year revenue outlook. Its shares fell sharply following the announcement, with the reduced revenue guidance cited as the primary reason for the decline.
The company kept adjusted earnings guidance unchanged at $21–25 million, while its shares fell 20.6% in after-hours trading on November 11.
Read the full storyRevenue topped consensus expectations despite falling 17% year over year, while net income rose and adjusted operating profit improved; the company lowered its annual revenue forecast range.
A news feed summary confirmed the earnings announcement, while quarterly figures and full-year financial guidance remained unavailable for verification; the company had maintained its prior outlook in August.